Xtl Biopharmaceu Financials

Xtl Biopharmaceu (XTLB) reported $451K in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, Xtl Biopharmaceu (XTLB) reported a net income of -$1.0M in fiscal year 2024, with a net profit margin of -227.7%.

As of fiscal year 2024, Xtl Biopharmaceu (XTLB) had $371K in cash and equivalents against $138K in long-term debt.

Xtl Biopharmaceu (XTLB) had a net profit margin of -227.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

Xtl Biopharmaceu (XTLB) has a return on equity of -18.9% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

Xtl Biopharmaceu (XTLB) generated -$1.7M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Xtl Biopharmaceu (XTLB) generated -$1.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

Xtl Biopharmaceu (XTLB) had $8.6M in total assets as of fiscal year 2024, including both current and long-term assets.

Xtl Biopharmaceu (XTLB) invested $54K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Xtl Biopharmaceu (XTLB) had 881M shares outstanding as of fiscal year 2024.

Xtl Biopharmaceu (XTLB) had a current ratio of 0.61 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

Xtl Biopharmaceu (XTLB) had a debt-to-equity ratio of 0.03 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Xtl Biopharmaceu (XTLB) had a return on assets of -12.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2024 data, Xtl Biopharmaceu (XTLB) had $371K in cash against an annual operating cash burn of $1.6M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Xtl Biopharmaceu (XTLB) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Xtl Biopharmaceu (XTLB) has an earnings quality ratio of 1.58x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Xtl Biopharmaceu (XTLB) scores 27 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.